Zika Immunotherapy Boosts Aethlon Medical (AEMD); Upside Visualized In First Hawaiian (FHB)


Shares of Aethlon Medical, Inc. (Nasdaq:AEMD) soared more than 45% to touch a new 52-week high of $9.09 in early trade Thursday after the company said that in vitro studies demonstrated “rapid capture” of zika virus by its Aethlon Hemopurifier(R), showing a 95% clearance of zika virus from cell culture fluid and about 50% clearance of zika from human blood serum in 5.5 hours and 5 hours respectively

The medical device company expects to release its first quarter fiscal 2017 earnings report later today – August 11 – after the closing bell.

AEMD stock is changing hands at $7.86, up $1.62 (or +25.96%) with 841,280 shares traded so far, representing a large increase in activity versus its average volume (3m) of 23,053

Aethlon Medical , which focuses on creating devices for cancer, infectious disease and other life-threatening conditions, has 7.63M Shares Outstanding and AEMD stock one-year range is from $4.02 to $9.09 per share



Investment analysts at Compass Point initiated coverage on First Hawaiian, Inc. (Nasdaq:FHB) shares with a Buy rating and a price target of $29.00

The bank holding company recently completed its initial public offering of 24,250,000 shares at $23.00 per share.

FHB stock is trading in positive territory by 1.00% (or +$0.25) at $24.70, and 562,611 of its shares changed hands so far

First Hawaiian, which provides banking products and services to individuals and businesses, has 139.46M Shares Outstanding. FHB stock began trading on the NASDAQ Global Select Market a week ago.


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at http://galaxystocks.com/disclaimer/